Literature DB >> 33842938

Ablation of persistent atrial fibrillation: the added value of hybrid.

Bart Maesen1,2, Elham Bidar1,2, Justin Glm Luermans2,3, Jos G Maessen1,2.   

Abstract

Entities:  

Keywords:  Atrial fibrillation; Hybrid AF ablation; Thoracoscopic ablation; Transvenous ablation

Year:  2021        PMID: 33842938      PMCID: PMC8327200          DOI: 10.1093/ejcts/ezab170

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


× No keyword cloud information.
Not only is there a rising enthusiasm for hybrid approaches in the treatment of persistent atrial fibrillation (AF), but also more and more reports on its efficacy and safety are being published [1-3]. The concept of attacking the atrial substrate from the epicardium and endocardium seems only logical given the electro-pathological complexity of non-paroxysmal AF and the incomplete understanding of the underlying pathophysiological mechanisms. Our initial report on hybrid AF ablation introduced an approach that combined epicardial thoracoscopic ablation with transvenous endocardial ablation [4]. In this and following reports, epicardial ablation was performed with the use of biparietal bipolar radiofrequency (RF) clamps and linear uniparietal bipolar RF devices [4-6]. Besides this, other epicardial ablation strategies have been incorporated in a one- or two-staged hybrid approach [1, 7]. A good example is the current report of Lapenna et al. [7] reporting on a staged hybrid treatment of 50 patients with non-paroxysmal AF and dilated left atria. In this study, the epicardial part consisted of a box lesion ‘on bloc’ using a flexible catheter that allows the application of uni- and bipolar RF (Cobra-Fusion). After a mean of 2.2 months, 92% of patients underwent the 2nd stage endocardial procedure, in which touch-up ablation of surgical lesions was performed in 54% of patients and a cavo-tricuspid isthmus line was performed in 17% of patients. At 2 years, 65% of patients were in sinus rhythm without the use of antiarrhythmic drugs or electrical cardioversion and 82% were in sinus rhythm allowing antiarrhythmic drugs or electrical cardioversion. The authors are to be congratulated on these results and the completeness of their follow-up (98%). It is important to note that continuous implantable rhythm monitoring (ILR) was used for follow-up in this study [7]. To date, most reports on surgical or hybrid AF ablation are based on follow-up using Holter monitoring. Given the large temporal difference in rhythm assessment between both methods, the use of ILR potentially could lead to much lower success rates than the overall reported success rate of 70% after hybrid approaches using Holter monitoring [3]. It is reassuring that the current study of Lapenna et al. shows otherwise, and the results stand in striking contrast to those of the recent study of Haldar et al. [8]. The CASA-AF trial, randomizing non-paroxysmal AF patients to either thoracoscopic or catheter AF ablation, the follow-up with ILR showed that only 26% of patients were arrhythmia-free 1 year after thoracoscopic AF ablation [8]. However, a more extensive ablation strategy in the catheter group and potential limitation in surgical experience (only 20 procedures were minimally required) are important factors that contributed to these disappointing results, besides the fact that it was a none hybrid approach [8]. Despite the good results, the study of Lapenna et al. also has 2 major drawbacks. First, the left atrial appendage (LAA) was not addressed. It is our opinion that LAA management is key in surgical AF treatment. Next to the potential benefit on stroke rate [9], electrical isolation following LAA clipping, stapling or resection not only prevents triggers originating from the LAA but also results in mass reduction of the AF substrate, both mechanisms that can improve success rates on the long term [10]. In their study, Lapenna et al. could have addressed the LAA via the transverse sinus or by adding a short left thoracoscopic procedure. Second, in less than half of the patients (46%), the box was isolated during the endocardial procedure. This indicates that the Cobra-Fusion technique, despite its meticulous application, is not very effective in creating long-lasting transmural lesions but also demonstrates the added value of a hybrid approach.
  10 in total

1.  Hybrid thoracoscopic surgical and transvenous catheter ablation of atrial fibrillation.

Authors:  Laurent Pison; Mark La Meir; Jurren van Opstal; Yuri Blaauw; Jos Maessen; Harry J Crijns
Journal:  J Am Coll Cardiol       Date:  2012-07-03       Impact factor: 24.094

2.  Hybrid Convergent Procedure for the Treatment of Persistent and Long Standing Persistent Atrial Fibrillation: Results of CONVERGE Clinical Trial.

Authors:  David B DeLurgio; Karl J Crossen; Jaswinder Gill; Christopher Blauth; Saumil R Oza; Anthony R Magnano; Mark A Mostovych; Michael E Halkos; David R Tschopp; Faraz Kerendi; Tyler L Taigen; Christian C Shults; Manish H Shah; Anil B Rajendra; Jose Osorio; Jonathan S Silver; Bruce G Hook; David M Gilligan; Hugh Calkins
Journal:  Circ Arrhythm Electrophysiol       Date:  2020-11-13

3.  Hybrid versus catheter ablation in patients with persistent and longstanding persistent atrial fibrillation: a systematic review and meta-analysis†.

Authors:  Claudia A J van der Heijden; Mindy Vroomen; Justin G Luermans; Rein Vos; Harry J G M Crijns; Sandro Gelsomino; Mark La Meir; Laurent Pison; Bart Maesen
Journal:  Eur J Cardiothorac Surg       Date:  2019-09-01       Impact factor: 4.191

4.  Three-year follow-up of hybrid ablation for atrial fibrillation.

Authors:  Bart Maesen; Laurent Pison; Mindy Vroomen; Justin G Luermans; Kevin Vernooy; Jos G Maessen; Harry J Crijns; Mark La Meir
Journal:  Eur J Cardiothorac Surg       Date:  2018-04-01       Impact factor: 4.191

5.  Heart-team hybrid approach to persistent atrial fibrillation with dilated atria: the added value of continuous rhythm monitoring.

Authors:  Elisabetta Lapenna; Manuela Cireddu; Teodora Nisi; Stefania Ruggeri; Benedetto Del Forno; Fabrizio Monaco; Marta Bargagna; Giuseppe D'Angelo; Caterina Bisceglia; Simone Gulletta; Eustachio Agricola; Alessandro Castiglioni; Ottavio Alfieri; Michele De Bonis; Paolo Della Bella
Journal:  Eur J Cardiothorac Surg       Date:  2021-03-24       Impact factor: 4.191

6.  Left atrial appendage: an underrecognized trigger site of atrial fibrillation.

Authors:  Luigi Di Biase; J David Burkhardt; Prasant Mohanty; Javier Sanchez; Sanghamitra Mohanty; Rodney Horton; G Joseph Gallinghouse; Shane M Bailey; Jason D Zagrodzky; Pasquale Santangeli; Steven Hao; Richard Hongo; Salwa Beheiry; Sakis Themistoclakis; Aldo Bonso; Antonio Rossillo; Andrea Corrado; Antonio Raviele; Amin Al-Ahmad; Paul Wang; Jennifer E Cummings; Robert A Schweikert; Gemma Pelargonio; Antonio Dello Russo; Michela Casella; Pietro Santarelli; William R Lewis; Andrea Natale
Journal:  Circulation       Date:  2010-07-06       Impact factor: 29.690

7.  Unilateral Left-sided Thoracoscopic Ablation of Atrial Fibrillation.

Authors:  Bart Maesen; Mark La Meir
Journal:  Ann Thorac Surg       Date:  2020-03-04       Impact factor: 4.330

8.  Two-year follow-up of one-stage left unilateral thoracoscopic epicardial and transcatheter endocardial ablation for persistent and long-standing persistent atrial fibrillation.

Authors:  Carlo de Asmundis; Varnavas Varnavas; Juan Sieira; Erwin Ströker; Henrique E Coutiño; Muryo Terasawa; Juan Pablo Abugattas; Francesca Salghetti; Riccardo Maj; Osório Thiago Guimarães; Saverio Iacopino; Vincent Umbrain; Jan Poelaert; Pedro Brugada; Sandro Gelsomino; Gian-Battista Chierchia; Mark La Meir
Journal:  J Interv Card Electrophysiol       Date:  2019-09-13       Impact factor: 1.900

9.  Thoracoscopic Left Atrial Appendage Clipping: A Multicenter Cohort Analysis.

Authors:  Charlotte van Laar; Niels J Verberkmoes; Hendrik W van Es; Thorsten Lewalter; Gan Dunnington; Stephen Stark; James Longoria; Frederik H Hofman; Carolyn M Pierce; Dipak Kotecha; Bart P van Putte
Journal:  JACC Clin Electrophysiol       Date:  2018-05-02

10.  Catheter ablation vs. thoracoscopic surgical ablation in long-standing persistent atrial fibrillation: CASA-AF randomized controlled trial.

Authors:  Shouvik Haldar; Habib Rehman Khan; Vennela Boyalla; Ines Kralj-Hans; Simon Jones; Joanne Lord; Oluchukwu Onyimadu; Anitha Satishkumar; Toufan Bahrami; Anthony De Souza; Jonathan R Clague; Darrel P Francis; Wajid Hussain; Julian W Jarman; David Gareth Jones; Zhong Chen; Neeraj Mediratta; Jonathan Hyde; Michael Lewis; Raad Mohiaddin; Tushar V Salukhe; Caroline Murphy; Joanna Kelly; Rajdeep S Khattar; William D Toff; Vias Markides; James McCready; Dhiraj Gupta; Tom Wong
Journal:  Eur Heart J       Date:  2020-12-14       Impact factor: 29.983

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.